Premium
Intravenous ketamine infusion for a patient with treatment‐resistant major depression: a 10‐month follow‐up
Author(s) -
Kwon J. H.,
Sim W. S.,
Hong J. P.,
Song I. S.,
Lee J. Y.
Publication year - 2018
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12669
Subject(s) - medicine , ketamine , depression (economics) , treatment resistant depression , dosing , major depressive disorder , antidepressant , anesthesia , mood , psychiatry , hippocampus , economics , macroeconomics
Summary What is known and objective Ketamine in a subanaesthetic dose has been shown to produce rapid antidepressant effects. Here, we describe a long‐term follow‐up case of a Korean patient with severe major depression who received repeated ketamine intravenous therapy ( KIT ). Case description A 49‐year‐old woman with a 6‐year history of treatment‐resistant major depression was given KIT once every 1 or 2 weeks over 10 months, for a total of 36 treatments. Her mood stabilized, and she showed a nearly 50% reduction in the severity of her depressive symptom. What is new and conclusion Long‐term repeated KIT may be an option for alleviating treatment‐resistant and relapsing major depression. Further research and large clinical trials are needed on the optimum KIT protocol, including dose, dosing interval, total number of treatments and when to stop.